Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a “standard chemotherapy regimen”: The CASA randomized trial
Diana Crivellari(Centro di Riferimento Oncologico), Aron Goldhirsch(Istituti di Ricovero e Cura a Carattere Scientifico), Kathryn P. Gray(Dana-Farber Cancer Institute), Fabio Puglisi(University of Udine), Meredith M. Regan(Dana-Farber Cancer Institute), Monica Castiglione‐Gertsch(University of Geneva), Richard D. Gelber(Harvard University), Silvia Dellapasqua(Istituti di Ricovero e Cura a Carattere Scientifico), Rudolf Maibach(The Coordinating Center), Lorenzo Gianni, Marco Colleoni(European Institute of Oncology), Manuela Rabaglio(University Hospital of Bern), Simon Spazzapan(Centro di Riferimento Oncologico), Alan S. Coates(International Breast Cancer Study Group), Karen N. Price(International Breast Cancer Study Group), István Láng(National Institute of Oncology), Graziella Pinotti(Medica (Italy)), Jean-Marc Lüthi(Spital STS), Karin Ribi
Cited by 56
Related Papers
Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine Treatment
|New England Journal of Medicine|1994|3.7k
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
|Annals of Oncology|2013|3.7k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
|New England Journal of Medicine|2004|1.8k